Journal article

Right or Left Primary Site of Colorectal Cancer: Outcomes From the Molecular Analysis of the AGITG MAX Trial

Gonzalo Tapia Rico, Timothy Price, Niall Tebbutt, Jennifer Hardingham, Chee Lee, Luke Buizen, Kate Wilson, Val Gebski, Amanda Townsend

CLINICAL COLORECTAL CANCER | CIG MEDIA GROUP, LP | Published : 2019

Abstract

BACKGROUND: For metastatic colorectal cancer, previous reports have described differences in biology and outcome, including response to biologic agents, based on whether the primary tumor is right- or left-sided. We explored the molecular markers from the AGITG MAX trial. PATIENTS AND METHODS: The AGITG MAX trial was a randomized study comparing capecitabine versus capecitabine + bevacizumab versus capecitabine + bevacizumab + mitomycin C as first-line therapy in advanced colorectal cancer. Patients were classified as having right-sided (caecum to transverse colon) or left-sided (descending colon to rectum) disease according to anatomic location. Baseline characteristics and previously descr..

View full abstract

University of Melbourne Researchers